Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.

Clinical lung cancer - 1 Mar 2012

Pallis Athanasios G, Voutsina Alexandra, Kentepozidis Nikolaos, Giassas Stylianos, Papakotoulas Pavlos, Agelaki Sofia, Tryfonidis Kostas, Kotsakis Athanasios, Vamvakas Lambros, Vardakis Nikolaos, Georgoulias Vassilis

Abstract excerpt

BACKGROUND: The purpose of this study was to evaluate the efficacy of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Forty-nine previously untreated white patients who had stage IIIB/IV pulmonary adenocarcinoma or b...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma, Bronchiolo-Alveolar

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Erlotinib Hydrochloride

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Survival Rate

Source

Identifiers

PMID: 22000696
DOI: 10.1016/j.cllc.2011.08.004

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22000696-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.PMID 22000696Read ↗

EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.Semantic proximity Read ↗

Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.Semantic proximity Read ↗

Erlotinib in the first-line treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.Semantic proximity Read ↗

Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.Semantic proximity Read ↗

Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).Semantic proximity Read ↗

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.Semantic proximity Read ↗

Erlotinib in lung cancer - molecular and clinical predictors of outcome.Semantic proximity Read ↗

A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.Semantic proximity Read ↗

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).Semantic proximity Read ↗

Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.Semantic proximity Read ↗

Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.